Eli Lilly and Company
Prescription Drugs · Cardiometabolic Therapeutics

Eli Lilly and Company: Products & infrastructure

Eli Lilly and Company has 6 apps in the stores: 6,776 ratings and 101k+ downloads on Google Play.

Data updated Nov 22, 2026 · Back to the company report

Products

Eli Lilly and Company has 6 apps in the stores: 6,776 ratings and 101k+ downloads on Google Play.

6.8kStore ratings
101k+Google Play downloads
6Apps
$887.9Mpaid to US doctors in 2025
FDA approvalsnew drugs, biologics and high-risk devices, per Drugs@FDA and PMA · and 38 more records
Kisunla
Biologic (BLA) · BLA761248 · donanemab-azbt · injection
Jul 2024
Rezvoglar
Biologic (BLA) · BLA761215 · insulin glargine-aglr · injection
Dec 2021
Taltz
EU authorisation (EMA) · EMEA/H/C/003943 · ixekizumab · Psoriasis;Arthritis, Psoriatic;Axial Spondyloarthritis;Arthritis, Juvenile
Apr 2016
Portrazza
Biologic (BLA) · BLA125547 · necitumumab · intra-articular, intramuscular, intravitreal
Nov 2015
Cymbalta
New drug (NDA) · NDA022516 · duloxetine hydrochloride · oral
Nov 2010
Adcirca
New drug (NDA) · NDA022332 · tadalafil · oral
May 2009
Cymbalta
New drug (NDA) · NDA022148 · duloxetine hydrochloride · oral
Jun 2008
Evista
New drug (NDA) · NDA022042 · raloxifene hydrochloride · oral
Sep 2007
EU clinical trialsthe trials it sponsors, per the EU's CTIS register
A study of LY3971297 in Participants with Heart Failure
Human Pharmacology (Phase I)- Other · Heart Failure, Diastolic, Heart Failure, Systolic, Heart Fa… · Netherlands, Romania
Nov 2026
A Study of LY4152199 in Participants with Previously Treated B-cell Malignancies (BAF_FRontier-1)
Human Pharmacology (Phase I)- First administration to humans · B-Cell cancers · Italy, France, Denmark, Poland, Spain, Germany
Nov 2026
J2A-MC-GZVA:A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Onc…
Therapeutic confirmatory (Phase III) · Prehypertension, Prediabetic State, Overweight, Obesity, Ab… · Czechia, Germany, Spain
Oct 2026
J3R-MC-YDAS: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of O…
Therapeutic confirmatory (Phase III) · Cardiovascular Diseases, Diabetes Mellitus, Type 2, Overwei… · Spain, Poland, France, Italy, Germany, Czechia, R…
Oct 2026
A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participant…
Human Pharmacology (Phase I)- Other · Amyotrophic Lateral Sclerosis · Netherlands, Belgium, Germany, Spain
Sep 2026
J2A-MC-GZGY: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-…
Therapeutic confirmatory (Phase III) · Diabetes Mellitus, Type 2 · Italy, Spain, Belgium
Sep 2026
Payments to US doctorsCMS Open Payments - the maker's totals, no recipient
2025
general $55.7M · research $832.2M · 443,957 records
$887.9M
2024
general $54.7M · research $661.3M · 567,304 records
$716M
2023
general $44.5M · research $589.4M · 527,245 records
$633.9M
Compensation For Services Other Than Consulting, Including S
a kind of payment, 2025
$34.5M
Food And Beverage
a kind of payment, 2025
$8.9M
Consulting Fee
a kind of payment, 2025
$8.4M
Zepbound
a product, 2025
$9.8M
Mounjaro
a product, 2025
$9.2M
Ebglyss
a product, 2025
$8.8M
Clinical trialsthe studies it sponsors or works on, per ClinicalTrials.gov · and 2,343 more records
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
phase 2 · under way · 161 participants · Urinary Bladder Neoplasms; Urologic Neoplasms; Receptor, Fibroblast Growth Fact…
Dec 2026
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants
phase 1 · under way · 64 participants · Healthy Participants
Dec 2026
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiova…
phase 3 · under way · 3,000 participants · Obesity; Overweight; Cardiovascular Diseases; Diabetes Mellitus, Type 2
Dec 2026
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
phase 1 · under way · 370 participants · Endometrial Neoplasms; Ovarian Neoplasms; Neoplasms, Germ Cell and Embryonal; C…
Dec 2026
A Study of LY3981314 in Participants With Autoimmune Hepatitis
phase 1 · under way · 12 participants · Hepatitis Autoimmune Disease; Hepatitis
Dec 2026
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Proble…
phase 3 · under way · 192 participants · Obesity; Overweight
Dec 2026
A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Brea…
phase 2 · under way · 120 participants · Breast Neoplasms
Dec 2026
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
phase 3 · under way · 2,115 participants · Obesity
Dec 2026
FDA 510(k) clearancesmedical devices cleared for the US market
Tempo Smart Button
K212217 · Class 2 · General Hospital
Sep 2022
Go Dose System
K160949 · Class 2 · Anesthesiology
Dec 2016
HumaPen Savvio
K160668 · Class 2 · General Hospital
Jun 2016
HumanPen Ergo II
K151686 · Class 2 · General Hospital
Dec 2015
HumaPen Luxura
K142518 · Class 2 · General Hospital
Jun 2015
HUMAPEN LUXURA HD
K100988 · Class 2 · General Hospital
Aug 2010
HUMAPEN LUXURA HD
K063151 · Class 2 · General Hospital
Jan 2007
HUMAPEN MEMOIR
K053563 · Class 2 · General Hospital
Apr 2006
Apps
App Store · 5,584 ratings · Medical · Eli Lilly and Company
4.8 ★
Google Play · 1,180 ratings · 100k+ downloads · Eli Lilly and Company
4.7 ★
Google Play · 500+ downloads · Eli Lilly and Company
App Store · 6 ratings · Business · Eli Lilly and Company
3.7 ★
App Store · 5 ratings · Business · Eli Lilly and Company
5.0 ★
App Store · 1 ratings · Health & Fitness · Eli Lilly and Company
1.0 ★
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.

Infrastructure

Eli Lilly and Company holds 5 MW of generating capacity in 1 US power plants (EIA-860, 2025).

5 MWUS generating capacity
1US power plants
Power plantsEIA-860
Lilly Technical Center
IN · Petroleum Liquids · operator Eli Lilly and Company · eia.gov ↗
5 MW
Power plants: EIA-860 - the operating utility holds a solely owned generator, each owner its percent of a jointly owned one; nameplate capacity of operable generators; each plant links its EIA page.